The basic question when investigating chemokine autocrine signaling in cancer, such as presented by CCL5/CCR5 axis, is “what activates what,” whereas in paracrine signaling in heterogeneous cancers the question is “what attracts what.” Autocrine signaling means that GB cells express both ligand and receptor, and thus activate the pathways downstream of CCR5 in a cell-autonomous manner. This evidence concerns the gene CCL5 and cancer.